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Background: Recent pivotal studies have shown that biodegradable polymer biolimus-eluting stent (BES) is as safe and efficacious as the current 
standard of a thin-strut everolimus-eluting stent (EES) with a durable biocompatible polymer. However, the effectiveness of BES in areal-world setting 
of diabetic patients is currently unclear.
methods: We enrolled 1266 consecutive patients with the NOBORI BES, 563 (44.5%) of whom had diabetes mellitus (DM). As a historical control 
group, a total of 1043 consecutive patients with the XIENCE/PROMUS EES between February 2010 and April 2011 were enrolled, 466 (44.7%) 
of whom had DM. The primary endpoint was the rate of major adverse cardiovascular events (MACE), defined as a composite of cardiac death, 
myocardial infarction, definite stent thrombosis, clinically driven target lesion revasculization (TLR) at 1-year.
results: Baseline characteristics were similar between the BES and EES groups. Patients with insulin dependent and multivessel coronary disease 
were similar between the 2 groups (20.6% vs. 20.6%, P=0.99; 34.3% vs. 28.4%, P=0.20, respectively). At 1-year, the incidence of MACE was not 
significantly different between the BES and EES group (8.9% vs. 7.3%, P=0.28). Cumulative incidence of myocardial infarction, definite stent 
thrombosis, and clinically driven TLR were not significantly different between the 2 groups (1.0% vs. 0.9%, P=0.71, 0.9% vs. 0.9%, P=0.94; 7.3% vs. 
4.7%, P=0.08, respectively). The incidence of TLR and Target vessel revasculization (TVR) was not significantly different between the 2 groups (11.9 
vs. 11.6, P=0.58; 13.7% vs. 12.2%, P=0.40, respectively). At Cox regression analysis, predictor of 1-year MACE were left ventricular ejection fraction 
<40%, hemodialysis, and prior coronary intervention.
conclusion: One-year clinical outcome after biodegradable polymer BES implantation in diabetic patients is not significantly different from that 
after durable polymer EES. This study suggests that both BES- and EES-use are acceptable in a real-world setting of diabetic patients.
